pCDCAR1 CD19 h(2B4ζ)(CAR-MZ096)
The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of NK cells to target human CD19. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to 2B4 and TCRζ signaling domains. And the vector product was designed for the treatment of Leukemia and Neuroblastoma.
Targeting Cell Type
Leukemia and Neuroblastoma
Discription of Signaling Cassetes
CD244 (Cluster of Differentiation 244) is a human protein encoded by the CD244 gene. It is also known as Natural Killer Cell Receptor 2B4. This gene encodes a cell surface receptor expressed on natural killer cells (NK cells) (and some T cells) mediating non-major histocompatibility complex (MHC) restricted killing. The interaction between NK-cell and target cells via this receptor is thought to modulate NK-cell cytolytic activity. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. CD244 can also be expressed on non-lymphocytes such as eosinophils, mast cells and dendritic cells.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CD19 (47G4) h(CD28-CD27-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (104875) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 scFv h(CD3ζ) CART, pCDCAR1
||Anti-CD19 scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1
||Anti-CD19 (S2) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (Denintuzumab) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (FMC63) h(41BB-CD3ζ, K4/E4) Conditional CAR, pCDCAR1
||Anti-CD19 scFv h(CD28-FcεRIγ) CART, pCDCAR1
||Anti-CD19 (SJ25C1) h(DAP10-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD3ζ-DAP10, SJ25C1) Viral Particle